Latest Takeda Pharmaceutical Company Stories
Plaintiff's lawyer promises appeal of judge's decision against California man in first U.S. Actos bladder cancer allegations trial over claims that use of diabetes drug can allegedly lead to bladder cancer. San Diego, CA (PRWEB) May 25, 2013 http://www.resource4thepeople.com/defectivedrugs/Actos-Bladder-Cancer-Lawsuit.html Resource4thePeople is updating consumers today with news of a judge's overturning of a jury's award of $6.5 million in damages to a California man in...
The Firm is currently evaluating Actos lawsuits on behalf of Individuals who developed bladder cancer, allegedly due to long-term use of Actos. New York, New York (PRWEB) May 25, 2013 Actos lawsuit claims pending in a federal multidistrict litigation underway in U.S. District Court, Western District of Louisiana, continue to move forward, Bernstein Liebhard LLP reports. According to a Case Management Order issued on May 21st, the Court has established procedures that govern the filing of...
Actos (pioglitazone) is a Type 2 diabetes drugs that was approved by the U.S. Food and Drug Administration (FDA) in 1999. Parker Waichman LLP has filed a lawsuit on behalf of a South Dakota man who took the drug, and alleges that it caused his bladder cancer; the case is one of thousands filed into the Actos multidistrict litigation, where Jerrold S. Parker, founding partner of Parker Waichman LLP, serves on the Plaintiffs’ Steering Committee. New York, NY (PRWEB) May 20, 2013 Parker...
The Firm is currently evaluating Actos lawsuits on behalf of long-term users of the drug who were diagnosed with bladder cancer. New York, New York (PRWEB) May 19, 2013 Actos lawsuit claims continue to move forward in a federal litigation now underway in U.S. District Court, Western District of Louisiana. According to a Case Management Order dated May 3rd, the Court has modified the litigation’s Bellwether Nomination process, reducing the Bellwether Nominee Pool to eight cases rather...
Parker Waichman LLP has filed a lawsuit alleging that Actos (pioglitazone) caused bladder cancer and the subsequent wrongful death of an Ohio man. Actos is a drug used to treat Type 2 diabetes; the FDA has warned that it can increase the risk of bladder cancer after one year of therapy. New York, New York (PRWEB) May 14, 2013 Parker Waichman LLP, a national law firm dedicated to protecting the rights of victims injured by defective drugs, has filed a lawsuit on behalf of the estate of an...
BETHESDA, Md., May 13, 2013 /PRNewswire-USNewswire/ -- Today, the American Gastroenterological Association announced that Takeda Pharmaceuticals U.S.A., Inc. will provide a $1.5 million unrestricted grant to the AGA Research Foundation endowment. This grant to the AGA Research Foundation endowment funds research and discoveries in gastroenterology, and supports young investigators across the United States. The AGA Research Foundation provides research grants to investigators in...
According to court documents, on May 9, 2013, two men filed a lawsuit in North Dakota District Court alleging they suffer from bladder cancer caused by Actos. In light of this news, AttorneyOne, a recognized authority on law, informs that they are now providing advice, including how to get in contact with legal counsel, to people potentially affected by Actos side effects. San Diego, CA (PRWEB) May 13, 2013 AttorneyOne.com, a recognized authority on law, updated the website recently and...
Parker Waichman LLP has filed a lawsuit on behalf of a Missouri man who allegedly developed bladder cancer after taking Actos (pioglitazone) for five years. Allegedly, the drug’s manufacturer, Takeda, knew that taking Actos could boost the chances of the patient developing bladder cancer but did not warn him or other consumers. New York, NY (PRWEB) May 08, 2013 Parker Waichman LLP, a national law firm dedicated to protecting the rights of victims injured by defective drugs, has filed a...
OSAKA, Japan, May 9, 2013 /PRNewswire/ -- Takeda Pharmaceutical Company Limited ("Takeda", "the Company") announced today the consolidated financial results for the fiscal year ended March 31, 2013, and forecasts of consolidated results for the fiscal year ending March 31, 2014. The Company is listed on the Tokyo Stock Exchange, First Section with the stock code "4502" and prepares financial statements according to Japan GAAP. Fiscal 2011 Fiscal...
Obtains Promising Vaccine Candidates Against Dengue and Hand, Foot and Mouth Disease, Advancing Takeda's Commitment to Vaccines and Global Health OSAKA, Japan and DEERFIELD, Ill. and FORT COLLINS, Colo., May 7, 2013 /PRNewswire/ -- Takeda Pharmaceutical Company Limited ("Takeda") and Inviragen, Inc. ("Inviragen") jointly announced today that Takeda, its wholly owned subsidiary Takeda America Holdings, Inc., and Inviragen, Inc. have entered into a definitive agreement for Takeda to...
